Most of the PubMed material consists of abstracts on preclinical research involving single cannabinoid molecules, test tubes, petri dishes, animal experiments, and in some cases human cell line studies.

Although all mammals have cell receptors that respond pharmacologically to cannabinoid compounds, data from animal experiments and other preclinical research is not always applicable to human experience.

GW Pharmaceuticals has conducted successful clinical trials of Sativex, the whole plant CBD-rich cannabis extract, mainly for people suffering from neuropathic pain; summaries of this research are also included. There have been additional clinical studies with synthetic CBD in Brazil and Israel. Unfortunately, political constraints stemming from cannabis prohibition have blocked clinical-oriented CBD research in the United States.

Most of the reports that follow pertain specifically to cannabidiol. Occasionally these articles examine the therapeutic potential of other plant cannabinoids – THC, CBDA (cannabidiol in its raw acid form), THCV, CBG, and CBDV, for example. We’ve also included a few PubMed studies that illuminate various aspects of the endocannabinoid system without focusing on CBD.

Select a condition to see the scientific evidence for CBD-rich cannabis.